Bisphosphonate-associated osteonecrosis of the jaw

Canadian Family Physician

Volumn 54, Issue 7, 2008, Pages 1019-1021

  Khan, Aliya ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b Canadian Task Force on Osteonecrosis of the Jaw ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; GLUCOCORTICOID;

BONE METASTASIS; BONE NECROSIS; CANCER PATIENT; DIET SUPPLEMENTATION; DRUG MEGADOSE; HUMAN; HYPERCALCEMIA; JAW DISEASE; LOW DRUG DOSE; METABOLIC BONE DISEASE; MORBIDITY; MOUTH HYGIENE; OSTEOPOROSIS; SHORT SURVEY; TREATMENT DURATION;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CANADA; DIPHOSPHONATES; HUMANS; JAW; JAW DISEASES; OSTEONECROSIS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 48249133659     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (31)

1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61(9):1115-7.
2. Favus MJ. Diabetes and the risk of osteonecrosis of the jaw [editorial]. J Clin Endocrinol Metab 2007;92(3):817-8.
3. Khan AA, Sándor GKB, Dore E, Morrison AD, Alsahli M, Amin F, et al. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2008 Jun 1. Epub ahead of print. Available from: http://jrheum.com/earlyrelease.html. Accessed 2008 May 30.
4. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65(3):369-76.
5. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62(5):527-34.
6. Kademani D, Koka S, Lacy MQ, Rajkumar SV. Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc 2006;81(8):1100-3.
7. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Eng J Med 2007;1(11):nihpa40967.
8. Brown JP, Josse RG. Scientific Advisory Council of the Osteoporosis Society of Canada: 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;167(10 Suppl):S1-34.
9. Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20(17):3719-36.
10. Berry S, Waldron T, Winquist E, Lukka H. The use of bisphosphonates in men with hormone-refractory prostate cancer. Practice guideline report No. 3-14. Toronto, ON: Cancer Care Ontario; 2005. Available from: www.cancercare.on.ca/pdf/pebc3-14s.pdf. Accessed 2008 May 30.
11. Berry S, Waldron T, Winquist E, Lukka H. The use of bisphosphonates in men with hormone-refractory prostate cancer: a systematic review of randomized trials. Can J Urol 2006;13(4):3180-8.
12. Hillner BE, Ingle JN, Chlebowski R, Gralow J, Yee JC, Janjan NA, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21(21):4042-57.
13. Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007;25(17):2464-72.
14. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94(19):1458-68.
15. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22(10):1479-91.
16. Peters E, Lovas GL, Wysocki GP. Lingual mandibular sequestration and ulceration. Oral Surg Oral Med Oral Pathol 1993;75(6):739-43.
17. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23(34):8580-7.
18. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63(11):1567-75.
19. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65(3):415-23.
20. Dimitrakopoulos I, Magopoulos C, Karakasis D. Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases. Int J Oral Maxillofac Surg 2006;35(7):588-93.
21. Cafro AM, Barbarano LA, Andriani A. Osteonecrosis of the jaw associated with chronic bisphosphonates therapy: an Italian experience [abstract]. Blood 2005;106(11):5152a.
22. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006;91(7):968-71.
23. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaws and bisphosphonates. N Engl J Med 2005;353(1):99-102.
24. Tosi P, Zamagni E, Cangini D, Tacchetti P, Offidani M, Ronconi S, et al. Bisphosphonates and osteonecrosis of the jaws: incidence in a homogeneous series of patients with newly diagnosed multiple myeloma treated with zoledronic acid [abstract]. Blood 2005;106(11):3461a.
25. Felsenberg D, Hoffmeister B, Amiling M. Bisphosphonattherapie assoziierte. Kiefernekrosen Deutsches Arzteblatt. In press.
26. Lam DK, Sándor GK, Holmes HI, Evans AW, Clokie CM. A review of bisphosphonate-associated osteonecrosis of the jaws and its management. J Can Dent Assoc 2007;73(5):417-22.
27. Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007;25(17):2464-72.
28. Zavras AI, Zhu S. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis? J Oral Maxillofac Surg 2006;64(6):917-23.
29. Melo M, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy. Strategies for prevention and early recognition. J Am Dent Assoc 2005;136(12):1675-81.
30. Ruggiero S, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2006;2(1):7-14.
31. Farah CS, Savage NW. Oral ulceration with bone sequestration. Aust Dent J 2003;48(1):61-4.